[go: up one dir, main page]

UY34791A - N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2- dihidroquinolina-3-carboxamida - Google Patents

N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2- dihidroquinolina-3-carboxamida

Info

Publication number
UY34791A
UY34791A UY0001034791A UY34791A UY34791A UY 34791 A UY34791 A UY 34791A UY 0001034791 A UY0001034791 A UY 0001034791A UY 34791 A UY34791 A UY 34791A UY 34791 A UY34791 A UY 34791A
Authority
UY
Uruguay
Prior art keywords
methyl
pentahydroxyhexyl
dihydroquinoline
carboxamide
oxo
Prior art date
Application number
UY0001034791A
Other languages
English (en)
Inventor
Laxer Avital
Ulanenko Konstantin
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY34791A publication Critical patent/UY34791A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica que contiene laquinimod o una sal farmacéuticamente aceptable del mism o, un compuesto aislado de N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6- pentahidroxihexil)amino)-2-oxo-N-fenil-1,2-dihidroquinolina-3-carboxamida o una sal del mismo, composiciones que contienen N-etil-4-hidroxil-1-metil-5 5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-N-fenil-1,2-dihidroquinolina-3-carboxamida y métodos para su preparación
UY0001034791A 2012-05-08 2013-05-07 N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2- dihidroquinolina-3-carboxamida UY34791A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261644054P 2012-05-08 2012-05-08

Publications (1)

Publication Number Publication Date
UY34791A true UY34791A (es) 2013-11-29

Family

ID=49551433

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034791A UY34791A (es) 2012-05-08 2013-05-07 N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2- dihidroquinolina-3-carboxamida

Country Status (19)

Country Link
US (1) US8809537B2 (es)
EP (1) EP2697201A4 (es)
KR (1) KR20150022816A (es)
CN (1) CN104395291B (es)
AR (1) AR090975A1 (es)
AU (1) AU2013259779B2 (es)
BR (1) BR112014028121A2 (es)
CA (1) CA2873258A1 (es)
EA (1) EA201492029A1 (es)
HK (1) HK1207080A1 (es)
IL (1) IL235338A0 (es)
IN (1) IN2014MN02485A (es)
MX (1) MX2014013664A (es)
NZ (1) NZ630549A (es)
SG (1) SG11201407447XA (es)
TW (1) TW201350467A (es)
UY (1) UY34791A (es)
WO (1) WO2013169746A2 (es)
ZA (1) ZA201408825B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN104955522A (zh) 2012-11-07 2015-09-30 梯瓦制药工业有限公司 拉喹莫德胺盐
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2159804A (en) * 1937-11-23 1939-05-23 Du Pont N-nitroaryl polyhydroxy alkyl amino compounds and process of preparing the same
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US4782155A (en) 1986-03-19 1988-11-01 Banyu Pharmaceutical Co., Ltd. Cephalosporin derivatives, processes for their preparation and antibacterial agents
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
US5139878A (en) 1991-08-12 1992-08-18 Allied-Signal Inc. Multilayer film constructions
US6043006A (en) * 1997-09-04 2000-03-28 Fuji Photo Film Co., Ltd. 4-(N,N-dialkylamino)aniline compound, photographic processing composition containing the same and color image-forming method
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
CA2376202C (en) 1999-06-07 2008-11-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
CA2625287C (en) 2005-10-19 2016-07-26 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
EA018031B1 (ru) 2006-06-12 2013-05-30 Тева Фармасьютикал Индастриз, Лтд. Стабильные препараты лаквинимода
WO2008131259A1 (en) 2007-04-19 2008-10-30 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
PL2682120T3 (pl) * 2007-12-20 2017-02-28 Teva Pharmaceutical Industries, Ltd. Stabilne preparaty lakwinimodu
EP2337779B1 (en) 2008-09-03 2017-04-19 Teva Pharmaceutical Industries Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
EP2376456A2 (en) * 2008-12-17 2011-10-19 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
KR20170109091A (ko) 2009-06-19 2017-09-27 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 다발경화증의 치료
KR20160148050A (ko) 2009-07-30 2016-12-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 크론병의 치료
PL3064206T3 (pl) 2009-08-10 2020-02-28 Active Biotech Ab Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
EA201290860A1 (ru) 2010-03-03 2013-04-30 Тева Фармасьютикал Индастриз Лтд. Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
WO2011109536A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus arthritis using laquinimod
JP2013521303A (ja) 2010-03-03 2013-06-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを使用したループス腎炎の治療
US8580819B2 (en) 2010-07-09 2013-11-12 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
KR20130041193A (ko) 2010-07-09 2013-04-24 테바 파마슈티컬 인더스트리즈 리미티드 5-클로로-4-하이드록시-1-메틸-2-옥소-n-페닐-1,2-다이하이드로퀴놀린-3-카복스아마이드, 염 및 그의 용도
JP2012047974A (ja) * 2010-08-26 2012-03-08 Toshiba Corp 映像表示装置及び映像表示方法
US8962598B2 (en) * 2010-10-14 2015-02-24 Immunahr Ab 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators
CA2820586A1 (en) 2010-12-07 2012-06-14 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
CN103781355A (zh) 2011-07-28 2014-05-07 泰华制药工业有限公司 用拉喹莫德与干扰素-β的组合治疗多发性硬化症
AU2012286699A1 (en) 2011-07-28 2014-03-13 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Also Published As

Publication number Publication date
ZA201408825B (en) 2016-07-27
KR20150022816A (ko) 2015-03-04
US20130345256A1 (en) 2013-12-26
WO2013169746A3 (en) 2013-12-05
WO2013169746A2 (en) 2013-11-14
MX2014013664A (es) 2015-04-17
NZ630549A (en) 2016-01-29
IN2014MN02485A (es) 2015-07-17
BR112014028121A2 (pt) 2017-06-27
EP2697201A2 (en) 2014-02-19
CN104395291B (zh) 2017-07-28
CN104395291A (zh) 2015-03-04
AR090975A1 (es) 2014-12-17
EP2697201A4 (en) 2014-11-26
IL235338A0 (en) 2014-12-31
AU2013259779A1 (en) 2014-12-18
TW201350467A (zh) 2013-12-16
EA201492029A1 (ru) 2015-06-30
CA2873258A1 (en) 2013-11-14
SG11201407447XA (en) 2015-02-27
HK1207080A1 (en) 2016-01-22
US8809537B2 (en) 2014-08-19
AU2013259779B2 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
UY34765A (es) Compuestos novedosos.
UY34515A (es) Triazolopiridinas sustituidas
UY34374A (es) Benzilindazoles sustituidos
UY34559A (es) Inhibidores de bromodominios
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34817A (es) Tienopirimidinas
UY34034A (es) Triazolopiridinas
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UY34039A (es) Compuestos fungicidas
UY4169Q (es) Altoparlante
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY33978A (es) Piridinonas bicíclicas nuevas.
UY34763A (es) Inhibidores de la agregación plaquetaria
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34885A (es) Proteínas de unión anti-mesotelina
UY34006A (es) Imidazopiridazinas
UY4234Q (es) Configuración aplicada en zapato
UY34302A (es) COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA
UY34503A (es) ?sal de bromhidrato de pridopidina?
UY4149Q (es) Golosina para mascota
UY34329A (es) Compuestos de triazolopiridina
UY34863A (es) Antagonistas de iap
UY33976A (es) Derivados de pirazolo-pirimidina.
UY34791A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2- dihidroquinolina-3-carboxamida
UY34553A (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210528